Markets

Vanda Pharmaceuticals' Phase III Clinical Study Of VQW-765 In Adults With Social Anxiety Disorder Did Not Meet Its Primary Endpoint; VQW-765 Was Safe And Well-Tolerated

Oct 14, 2026 · 05:03 PM ET· updated 1h ago

Phase III clinical study of VQW-765 in adults with social anxiety disorder did not meet its primary endpointConsistent with prior studies, VQW-765 was safe and well toleratedWASHINGTON, Oct. 14, 2026 /PRNewswire/ --

Why It Matters

Vanda's new medicine for anxiety didn't work as well as hoped. The drug was safe, but companies need medicines that actually help patients to succeed.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

VNDA4.10

-0.20 (-4.65%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.